Text {#Sec1}
====

Transporters of epithelial membranes arguably represent a vertebrate organism's most significant collective array of regulatory mechanisms that control the intermediary metabolism of amino acids. Such transporters control metabolic reactions by regulating throughput of substrates and products, and creating steady state pools of metabolites. Epithelial membrane transporters modulate metabolic flows and pools of both the proteinogenic and the nonproteinogenic amino acids. Working in conjunction with one another, amino acid transporters maintain coordination and integrity of metabolic events within tissues and even between organs.

This chapter reviews the current understanding of amino acid transport systems and transporters in basolateral membranes and apical membranes of epithelial cells in humans and other vertebrates. The chapter content is focused on transporters and transport systems that serve amino acids which are either nonproteinogenic or proteinogenic nutrients and metabolites, although some transporter genes and polypeptides are technically subsets categorized within larger groupings that are structurally and mechanistically related to the neurotransmitter transporters \[[@CR1]\]. Also, many apparently unrelated so-called transporter "orphan" genes have been historically clustered as a single branch off the SLC6 neurotransmitter superfamily, although they are now emerging as actually being epithelial amino acid transporters related in structure, function, and probably oligomeric association in the membrane \[[@CR2], [@CR3]\].

This chapter attempts to catalog the body of literature encompassing the epithelial barriers of the kidney, gastrointestinal tract, lung, cornea, liver, gallbladder, and other tissues. The reader is directed to several fine reviews \[[@CR4]--[@CR8]\] that delve into other details of renal and intestinal absorptive epithelial membranes in physiological processes or their involvement in absorptive pharmacokinetics \[[@CR9]\] of monomer amino acids or natural dipeptides and drug analogues \[[@CR10], [@CR11]\].

The concept of membrane transport physiology involves physical entities of discrete transporter genes and expressed polypeptides, in addition to the interactions and functionality of these units. "Transporter" and "transport system" are colloquially -- although incorrectly -- thought of as one and the same entity. Although a transporter's functional activity can indeed occur by the action of a single species of monomeric transporter protein, there are many instances of amino acid transport functional activity that are catalyzed only by the concerted interaction of multiple subunit proteins in the membrane. This latter scenario is termed a "transport system," which is comprised of multimeric arrangement of transporter proteins, usually as heterodimers.

Monomeric Transporter Proteins, Genes, and Transport Systems {#Sec2}
============================================================

Table [1](#Tab15_1_149577_1_En){ref-type="table"} summarizes the known monomeric transporter proteins involved in epithelial regulation of amino acid movement across apical and basolateral membranes. Although most work has been done for small intestinal and renal transport, representation occurs for colon, liver, lung, cornea, adipose, testis, stomach, choroid plexus, and placenta. There is evidence for some SLC6 family members to form oligomers/homodimers \[[@CR12], [@CR13]\] in nonepithelial membranes, but this has not been confirmed for epithelial cell membranes. Further studies in this arena may indeed uncover that all SLC6 members form oligomers. Table 1Monomeric amino acid transporters and transport systems in epithelial membranes. Transporters are grouped by SLC (solute carrier) gene families \[[@CR1]\], utilizing Human Genome Organization (HUGO) Nomenclature Committee classifications \[[@CR14]\]. Functional transport systems are named using the Christensen naming plan \[[@CR15]\]. Expression and localization derived from the Swedish Human Proteome Resource \[[@CR69]\]. There is evidence for some SLC6 family members to form oligomers/homodimers \[[@CR12], [@CR13]\] in nonepithelial membranes, but this has not been established for epithelial cellsTransport "system" functional nameMonomer protein common aliasGeneHuman gene locusSequence accession IDRepresentative substratesIon dependencyTissue epitheliumMembrane location**SLC1 family**X~AG~ ^−^EAAT3SLC1A19q24NM_004170[l]{.smallcaps}-glutamate, [d]{.smallcaps}/[l]{.smallcaps}-aspartate,cystine (SS)H^+^, Na^+^, K^+^Kidney (K), Intestine (I), liverApicalX~AG~ ^−^EAAT2SLC1A211p13--p12NM_004171[l]{.smallcaps}-glutamate, [d]{.smallcaps}/[l]{.smallcaps}-aspartate,cystine (SS)H^+^, Na^+^, K^+^LiverApicalASCASCT1SLC1A42p13−p15NM_003038Alanine, serine, threonine, cysteine, glutamineNa^+^Lung, stomach, K, I, corneaApicalASCASCT2 or ATB^0^SLC1A519q13.3NM_005628Alanine, serine, threonine, cysteine, glutamine, branched neutralsNa^+^K, I, lung, colonApicalX~AG~ ^−^EAAT5SLC1A71p32.3NM_006671[l]{.smallcaps}-Glutamate, [d]{.smallcaps}/[l]{.smallcaps}-AspartateH^+^, Na^+^, K^+^RetinaApical**SLC6 family**5-HTTSERTSLC6A417q11.1--q12NM_001045Serotonin, carnitine, organic cationsNa+, Cl^−^, K^+^β (beta)TAUTSLC6A63p25--p24NM_003043Taruine, β-alanine, GABANa^+^, Cl^−^K, retina, placentaBasolateralCreatineCRTRSLC6A8Xq28NM_005629CreatineNa^+^, Cl^−^K, I, retinaApicalGLYGLYT1SLC6A91p33NM_201649GlycineNa^+^, Cl^−^Lung, stomach retinaBasolateralGAT2GAT2SLC6A1312p13.3NM_016615GABANa^+^, Cl^−^K, retina, choroid plexusB^0,+^ATB^0,+^SLC6A14Xq23--q24NM_007231Neutrals and dibasics, arginine,[d]{.smallcaps}-serineNa^+^, Cl^−^ColonApicalGLYXTRP2SLC6A185p15.33NM_182632GlycineNa^+^, Cl^−^KApicalB^0^ (or B)B^0^AT1SLC6A195p15.33NM_001003841Neutrals, glutamineNa^+^K, I, placentaApicalIMINOSIT1SLC6A203p21.6NM_020208Proline, sarcosine, pipecolateNa^+^K, I, choroid plexus, stomach, colonApical**SLC7 family**y^+^CAT-1SLC7A113q12--q14NM_003045Arginine, ornithine, lysine, histidine, dibasicsNoneUniversalBasolateral**SLC15 family**Pept1PEPT1SLC15A113q33--q34NM_005073Dipeptides and tripeptides; carnosine, β-lactam antibiotics, angiotensin converting enzyme inhibitorsH^+^ with NHE3I, KApicalPept2PEPT2SLC15A23q13.3--q21NM_021082Dipeptides and tripeptidesH^+^ with NHE3I, K, lung, mammary glandApicalPTR4PHT1SLC15A412q24.32NM_145648Histidine, di-, tri-peptidesH^+^RetinaApical**SLC16 family**TTAT1SLC16A106q21--q22NM_018593Aromatics, [l]{.smallcaps}-DOPA−K, I, placentaBasolateral**SLC22 family**OCTN2VTOCTN2SLC22A55q23.3NM_003060[l]{.smallcaps}-carnitine, acetyl-[l]{.smallcaps}-carnitineNa^+^I, K, lung, liverApical**SLC36 family**IminoacidPAT1SLC36A15q33.1AF516142Proline, glycine, b-alanine, GABA, taurine, [d]{.smallcaps}-serineH^+^ with NHE3K, I, liver, lung, colonApicalIminoacidPAT2SLC36A25q33.1AY162214Proline, glycine, [l]{.smallcaps}-alanineH^+^ with NHE3K, LungApical**SLC38 family**ASNAT1SLC38A112q12--q13.11NM_0030674Glutaminealanine,asparagine,cysteine,histidine,serineNa^+^Placenta, retinaApicalASNAT2SLC38A212qNM_018976Alanine, asparagine, cysteine, glutamine, glycine, histidine, methionine, proline, serineNa^+^I, K, placenta, lung, liverBasolateralNSNAT3, SN1SLC38A33p21.3NM_006841Glutamine, histidineNa^+^, H^+^K, retinaBasolateralASNAT4SLC38A412q13NM_018018Alanine, asparagine, cysteine, glycine, threonineNa^+^K, liver, placentaBasolateralNSNAT5SLC38A5Xp11.23NM_033518Glutamine, histidine, serine, asparagine, alanineNa^+^ , H^+^I**SLC43 family**LAT3POV1SLC43A111p11.2NM_003627Branched chain amino acids, phenylalanineNoneKLAT4LAT4SLC43A217p13.3NM_152346Branched chain amino acids, phenylalaninineNoneI, K, placentaBasolateral

The components of [1](#Tab15_1_149577_1_En){ref-type="table"} are based on the Human Genome Organization (HUGO) Nomenclature Committee classification nomenclature \[[@CR14]\] for transporters as SLC families, with gene family refinement by Hediger et al. \[[@CR1]\] Transport "system" functional names are derived from the original nomenclature of Christensen \[[@CR15]\] as extended by many laboratories over the past several decades. Note that SLC genes can be grouped by the function of their expression product. In Table [1](#Tab15_1_149577_1_En){ref-type="table"} a given physiologically functional transporting system results from the activity of a single polypeptide expression product trafficked to the appropriate membrane.

So-called historically "orphan transporters" are now emerging as actually being clustered related amino acid transporters of the SLC6 family. The dendogram in Fig. [1](#Fig15_1_149577_1_En){ref-type="fig"} shows the mouse SLC6 series of transporter proteins. The human creatine transporter-2 (SLC6A10) apparently does not have an ortholog correlate in mouse.Fig. 1SLC6 family clustering of amino acid monomer transporters. Note that many apparently unrelated transporters have been historically clustered as a major branch of "orphans," although their transporter polypeptide structures and possible oligomeric relationships are currently being uncovered as related. In this dendogram, the human gene SLC number is listed above the common name for each polypeptide expression product. Adapted from laboratories of Broer \[[@CR2]\] and Verrey \[[@CR3]\]

One of the "orphan" family genes, SLC6A20, encodes the SIT1 transporter serving proline and imino analogues via the sodium-dependent "IMINO" system in the intestine (IMINO has been characterized in \[[@CR16]\]). In contrast, however, in the kidney and lung these substrates are served by the proton-activated "PAT/iminoacid" system which exhibits the activity profiles of two expressed transporter proteins PAT1 and PAT2, as encoded by the SLC36 family genes SLC36A1 and SLC36A2 (see Table [1](#Tab15_1_149577_1_En){ref-type="table"}). The latter genes reside on chromosome 5q33.1 in humans or 11B1.3 in mice, as shown in Fig. [2](#Fig15_2_149577_1_En){ref-type="fig"}. The human and mouse open reading frames are each encoded by ten exons. This figure shows an example of the genomic exon/intron organization of the SLC36 genes responsible for tissue-dependent differential expression of the transporters. Fig. 2Genomic exon/intron organization of the genes SLC36A1 (encoding PAT1) and SLC36A2 (encoding PAT2) on human chromosome 5q33.1. These genes are flanked by genes *FAT2* and *GM2A*, shown for orientation. The mouse orthologs are located on chromosome 11B1.3. Putative exons are represented by *vertical lines*. Adapted from Boll et al. \[[@CR66]\]

Heterodimer Regulation of Transport {#Sec3}
===================================

For several transporting systems, a multimeric arrangement of polypeptides is required for physiological activity. Table [2](#Tab15_2_149577_1_En){ref-type="table"} summarizes the well-established heterodimers required for these cases. Note that 4F2hc (alternative name CD98) is utilized as a subunit in many of these systems. Table 2Heterodimeric amino acid transporters and transport systems in epithelial membranes. Transporter SLC (solute carrier) gene family names \[[@CR1]\] are shown with Human Genome Organization (HUGO) Nomenclature Committee classifications \[[@CR14]\]. Functional transport systems are named using the Christensen naming plan \[[@CR15]\]. Expression and localization derived from the Swedish Human Proteome Resource \[[@CR69]\]. The heavy chain 4F2hc subunit is synonymously called CD98Transport "System" functional unit nameHeterodimer subunits; protein common aliasesSubunit genesHuman gene locusSequence accession IDRepresentative substratesIon dependencyTissue epitheliumMembrane locationAscasc1plus4F2hcSLC7A10plusSLC3A219q12--13.111q13NM_019849NM_002394Small neutral [l]{.smallcaps}- and [d]{.smallcaps}-amino acids, alanine, [d]{.smallcaps}-serine, cyst(e)ine, glycineNoneBasolateralb^0,+^b^0,+^ATplusrBATSLC7A9plusSLC3A119q13.12p16.3--p21NM_014270NM_000341Dibasics, arginine, cystine, large neutrals (exchange extracellular dibasics with intracellular neutrals)NoneI, K, placentaApicalLLAT1plus4F2hcSLC7A5plusSLC3A216q24.311q13NM_003486NM_002394Branched chain neutrals, [l]{.smallcaps}-DOPANoneI, placentaBasolateralLLAT2plus4F2hcSLC7A8PlusSLC3A214q11.211q13NM_012244NM_002394Branched chain neutrals (small and large)NoneI, K, placenta, stomachBasolateralx~c~ ^−^xCTplus4F2hcSLC7A11plusSLC3A24q28--q3211q13NM_014331NM_002394Cystine/glutamate exchangeNoneChoroid plexus, intestine, kidneyBasolateral (evidence in apical)y^+^Ly^+^LAT1plus4F2hcSLC7A7plusSLC3A214q11.211q13NM_003982NM_002394Lysine, arginine, dibasics, neutralsNone for dibasics; Na^+^ for large neutralsI, K, lungBasolateraly^+^Ly^+^LAT2plus4F2hcSLC7A6plusSLC3A216q22.1--22.211q13NM_003983NM_002394Lysine, arginine, dibasics, neutralsNone for dibasics; Na^+^ for large neutralsI, K, lungBasolateral

Subunit polypeptides of amino acid transporters play multiple roles in nonepithelial cell types, and it is likely that in epithelial membranes they also serve multiple roles. For example, CD98/4F2hc at the basolateral membrane of intestinal epithelium contains a PDZ class II-binding domain \[[@CR17]\] regulating integrin signaling, serving in such diverse roles as inflammation modulation, cell growth via mTOR \[[@CR4], [@CR18]\], cell adhesion, migration, and binding rotavirus enterotoxin \[[@CR19]\]. 4F2hc (CD98) forms a heterodimer with amino acid transporter subunits in basolateral membranes -- asc, LAT1, LAT-2, y^+^LAT1, y^+^LAT-2, and xCT -- thereby resulting in six different functional transport systems (Table [2](#Tab15_2_149577_1_En){ref-type="table"}). Burdo et al. \[[@CR20]\] reported evidence for xCT and 4F2hc in apical membranes of mouse and primate duodenum and renal tubules, as well as in choroid plexus although the particular membrane aspect was not specified for this brain tissue. In situ heterodimerization of y^+^LAT1 with 4F2hc has been visualized using acceptor photobleaching FRET microscopy \[[@CR21]\]. Figure [3](#Fig15_3_149577_1_En){ref-type="fig"} shows the diverse ways by which the 4F2hc subunit plays a role in modulating amino acid transport at the basolateral membrane. Fig. 3Interactions of subunit regulation of amino acid transport in intestinal basolateral membranes. Various example complexes are shown, including heterodimerization with LAT2, β~1~-integrins, and ICAM-1. 4F2hc (synonymous with CD98) modulates β~1~-integrin activation as well as activity of amino acid transport via LAT2. Furthermore, another polypeptide, ICAM-1, could independently modulate amino-acid transport activities via LAT2 at its extracellular C-terminal domain that contains a PDZ-binding domain. Adapted from Yan et al. \[[@CR17], [@CR67]\]

In addition to these 4F2hc basolateral systems, a separate dimerization coupling occurs at the apical surface which involves b^0,+^AT plus rBAT (Table [2](#Tab15_2_149577_1_En){ref-type="table"}). Extensive descriptions of models of the apical membrane heterodimer comprised of b^0,+^AT plus rBAT are presented elsewhere \[[@CR5], [@CR6], [@CR22]--[@CR26]\].

Mineralocorticoid receptors regulate at least some intestinal transporters. Work from Soares-da-Silva's laboratory \[[@CR27]\] demonstrates that chronic systemic aldosterone administration, acting through a spironolactone-sensitive mechanism, regulates rat intestinal LAT2 and 4F2hc subunit mRNA and protein expression as well as ASCT2 and LAT1 protein levels.

Dipeptide Transporters {#Sec4}
======================

Transepithelial movement of amino acids occurs by highly efficient transport of di- and tri-peptides across the apical membrane, with cytosolic hydrolysis by aminopeptidases then final basolateral transport of the constituent free amino acids. Proton-dependent secondary active transporters PEPT1 (SLC15A1) and PEPT2 (SLC15A2) are expressed in epithelia of small intestine, renal tubules, liver, and gallbladder. These transporters serve natural dipeptides, and are increasingly exploited for their ability to absorb certain oral pharmaceuticals as substrates \[[@CR10]\]. Some examples of substrates accommodated by PEPT1 are shown in Table [3](#Tab15_3_149577_1_En){ref-type="table"}. Brandsch and colleagues \[[@CR10]\] have extensively described peptidomimetic pharmaceutical substrates of PEPT1 and PEPT1. Table 3Natural peptides and pharmaceuticals interacting with PEPT1. Affinity constants *K* ~*i*~ were obtained in Caco-2 cell uptake competition assays. Adapted from Brandsch et al. \[[@CR10]\]PEPT1 substrate or inhibitor***K*** ~***i***~(mM)Affinity range (relative ***K*** ~***i***~)Lys\[ZNO~2~)\]--Val0.002High affinity (\<0.5 mM)Alafosfalin0.19Ala-Lys0.21Ceftibuten0.34Valaciclovir0.49Gly-Sar1.1Medium affinity (0.5--5 mM)Pro--Pro1.2δ-Aminolevulinic acid1.5Cloxacillin3.0Lys--Lys3.4[d]{.smallcaps}-Ala-Lys7.0Low affinity (5--15 mM)Cefadroxil7.2Pro-Ala9.54-Aminophenylacetic acid14Cephalexin14

It has become increasingly apparent that natural biological systems, PEPT1 and PEPT2 play roles other than simply nitrogen absorption for the host organism. For example, although PEPT1 is not normally expressed in colon, its expression is induced at the transcriptional level in pathological inflamed states of colonic epithelial cells in inflammatory bowel disorders such as ulcerative colitis or Crohn\'s disease \[[@CR28]\]. In this condition, bacterial metabolite dipeptides provide PEPT1 substrates absorbed intact into colonic cells and subsequently into the colonic lamina propria where immune cells reside \[[@CR28]\]. *Escherichia coli* pathogenic peptide metabolites include Ac-muramyl-Ala-Glu and N-formylmethionyl-leucyl-phenylalanine. This triggers an inflammatory response by induction of MHC I molecules and AP1 and NFκB-related pathways leading to cytokines and macrophage infiltration. In the inflamed state, the sustained luminal acidic state further drives colonic transepithelial transport of the bacterial peptides. The distribution of PEPT1 in various regions along the gut is shown in Fig. [4](#Fig15_4_149577_1_En){ref-type="fig"}. Fig. 4Relative mRNA expression of PEPT1 (SLC15A1) in various regions of the gastrointestinal tract. Data points from individual patients. Means are shown as *horizontal bars* for each intestinal region. Adapted from data of Meier et al. \[[@CR68]\]

Transepithelial Transport of Amino Acids {#Sec5}
========================================

Transepithelial movement of amino acids requires communication between events at the apical and basolateral membrane of a given tissue epithelium (Fig. [5](#Fig15_5_149577_1_En){ref-type="fig"}). The lion's share of amino acid transport occurs in the intestine and the renal nephron. Apical membrane transporters of small intestine and large intestine handle the fundamental interface between the entire internal milieu and the external world of nutrient nitrogen, while the kidney rescues filtered monomer amino acids as well as di- and tri-peptides in the form of the peptides' constituent free amino acids. Epithelial membrane systems of other tissues throughout the body provide a means of communication linking metabolic events among various organ systems. Fig. 5The fundamental concept of nutrient nitrogen digestion and absorption by small intestinal epithelium enterocytes. Luminal pancreatic peptidases (1) generate products of free amino acids, small di- and tri-peptide fragments, and residual large polypeptides. Enterocyte apical membrane-bound aminopeptidases (2) further hydrolyze large peptides to yield di- and tri-peptides. A variety of amino acid transport systems (3) move free amino acids across the apical membrane into the enterocyte cytosol. Certain di- and tri-peptides are absorbed intact into the cytosol via apical membrane transporters (4). Subsequently, cytosolic aminopeptidases (5) hydrolyze these peptides to generate free amino acids. The pool of free amino acids is then transported (6) across the basolateral membrane to the serosal side of the epithelium, and subsequently into the portal blood. In the interdigestive postprandial state, amino acids are taken up by the basolateral membrane from the blood. A variety of transporters are responsible for steps 3, 4, and 6, as detailed throughout the text and tables. Analogous events occur in the kidney lumen relating to degradation of peptide hormones, rescue of amino acids, and whole body nitrogen regulation

Thermodynamic Coupling {#Sec6}
======================

Secondary active transport of amino acids exploit epithelial transmembrane electrochemical gradients of Na^+^ and H^+^, and K^+^. As demonstrated by examples in Fig. [6](#Fig15_6_149577_1_En){ref-type="fig"}, the activation can occur by Na^+^ alone, H^+^ alone, Na^+^ plus H^+^, or by coordinated coupling of Na^+^ and H^+^ gradient by two different transport systems. In the case of indirect H^+^ coupling, apical NHE sodium/proton exchangers are the predominant players. In all cases, the Na^+^/K^+^ ATPase regulates Na^+^, K^+^, and electrical gradients sensed by the apical and basolateral sides. Gerencser and Stevens \[[@CR29], [@CR30]\] provide a quantitative explanation of thermodynamic coupling regarding amino acid transport. Fig. 6Schematic examples of ion-dependent coupling in amino acid transport at the apical membrane of an epithelium. *Left cell* shows a generic proton-dependent amino acid uptake coupled with Na^+^/H^+^ exchanger NHE3 (SLC9A3). The *center cell* shows a generic transporter coupling amino acid influx with Na^+^ influx, activated by the Na^+^ electrochemical potential across the apical membrane. The *right cell* shows active transport of anionic amino acids (e.g., glutamate or aspartate) via EAAT3 (SLC1A1) coupling to electrochemical gradients of Na^+^, H^+^, and K^+^. In all cases, transepithelial and epithelial cell membrane ion gradients and electrical potentials (ΔΨ) ultimately depend on the basolateral membrane Na^+^/K^+^-ATPase activity

Coordinated Thermodynamic and Metabolic Communication Among Amino Acid Transport Systems {#Sec7}
========================================================================================

Transport systems cooperate in a concerted manner to bring about net transepithelial transport, in addition to modulating the entire metabolism of amino acids. Membrane ion exchangers, primarily H^+^/Na^+^ electroneutral exchanger NHE3 and Na^+^/K^+^ ATPase, interject their important roles in modulating the activity of secondary active transporters of amino acids. Figure [7](#Fig15_7_149577_1_En){ref-type="fig"} demonstrates the coordination of selected transporter proteins and their functional transport systems in epithelial metabolism and movement of amino acids concerning the cytosol, and apical and basolateral membranes. In Fig. [7](#Fig15_7_149577_1_En){ref-type="fig"} note the coordination of TAT1 with LAT2/4F2hc which allows efflux of small neutral amino acids at the expense of cycling of aromatic amino acids \[[@CR31]\]. Also note the roles of the many transporter subunits involved in coupling and regulating movements of cationic and neutral amino acids. Table [4](#Tab15_4_149577_1_En){ref-type="table"} describes the manner by which the selectivities of all the cationic/dibasic amino acid transport systems are determined experimentally. Fig. 7Coordinated thermodynamic and metabolic communication among selected amino acid transport systems in epithelial membranes. Amino acids are shown as cationic (AA^+^), zwitterion neutral (AA^O^), anionic (AA^--^), or generic (AA). Ion exchangers interject their important roles in modulating the secondary active transporters of amino acids. Various mechanisms maintain pH \< 7 at the immediate apical membrane surface in various tissues. This figure is a generic representation of an epithelial cell, and not all shown transporters are in every tissue type. The role of ACE2 is described in the main text Table 4Determination of epithelial membrane cationic/dibasic amino acid transport systems' functional activities. Unlabeled amino acids in assay media are at concentrations \>100X concentration of \[^3^H\][l]{.smallcaps}-arginine. Modified from Bae et al. \[[@CR70]\]Transport "system" functional activity nameAssay conditions; uptake of \[^3^H\]**[l]{.smallcaps}**-arginineParallel transport systems potentially involved with assay conditionsCalculating \[^3^H\]**[l]{.smallcaps}**-arginine uptake via single target transport systemProtein subunits giving target transport system activity in epitheliumGenes encoding subunitsB^0,+^(a) Na^+^ ~,~ Cl^−^y^+^ ; y^+^L ; b^0,+^ ; B^0,+^B^0,+^ = (a) -- (b)ATB^0,+^SLC6A14b^0,+^(b) Na^+^ freey^+^ ; y^+^L ; b^0,+^b^0,+^ = (b) -- (c)b^0,+^ATplusrBATSLC7A9plusSLC3A1y^+^L(c) Na^+^ free plus [l]{.smallcaps}-alaniney^+^ ; y^+^Ly^+^L = (c) -- (d)y^+^LAT1 plus 4F2hc; ory^+^LAT2 plus 4F2hcSLC7A6 plusSLC3A2;or SLC7A7 plusSLC3A2y^+^(d) Na^+^ plus [l]{.smallcaps}-leuciney^+^y^+^ = (d)CAT-1SLC7A1

Nonproteinogenic Creatine in the Intestinal Epithelium {#Sec8}
======================================================

Creatine is an important amino acid that serves several critical roles in intestinal epithelial transport physiology and intermediary metabolism. A metabolic interplay exists between creatine absorption, arginine and leucine absorption, and gross control of epithelial absorption of other nutrients in these tissues \[[@CR32]--[@CR35]\]. A putative model of creatine (Cr^+^) absorption in renal or intestinal absorptive epithelium is shown in Fig. [8](#Fig15_8_149577_1_En){ref-type="fig"}. Na^+^ and Cl^−^-dependent creatine transport occurs across apical membranes and possibly basolateral membranes. In addition to transepithelial absorption, creatine enhances transepithelial absorption of other nutrients (glucose, other amino acids, etc) via villus contraction and pedundular motility through the actions of enterocyte actin-myosin as the result of entyerocyte creatine kinase Fig. 8Participation of nonproteinogenic creatine in intestinal epithelium physiology. Putative model of creatine (Cr^+^) absorption in renal or intestinal absorptive epithelium. The branched chain amino acid [l]{.smallcaps}-leucine or its keto analogue α-ketoisocaproic acid (KIC), or [l]{.smallcaps}-arginine, can initiate mTOR-dependent SLC6A8 trafficking

phosphorylation. Intracelluar trafficking of SLC6A8 proteins sequested in cytosolic endosomal vesicles is intiated by mammalian targeting of the rapamycin (mTOR) signaling pathway \[[@CR36]\]. The branched chain amino acid [l]{.smallcaps}-leucine or its keto analogue α-ketoisocaproic acid (KIC), or [l]{.smallcaps}-arginine, can initiate mTOR-dependent SLC6A8 trafficking.

A Major Transporter: SLC6A19 (B^0^AT1) {#Sec9}
======================================

A major functional transport system serving the nutrient zwitterionic amino acids, initially called System NBB (Neutral Brush Border) was originally described by Stevens \[[@CR37], [@CR38]\] using rabbit small intestinal brush border membrane vesicles. Stevens then renamed NBB as B^0^ in order to be consistent with the pattern of competitive inhibition observed for Van Winkle's "b" and "B" series of systems in blastocyte membranes \[[@CR39]\]. However, H. Christensen interjected (personal communications), requesting that the "^0^" superscript be dropped, with the argument that it was redundant in naming a sodium-dependent transport system which served only zwitterion substrates. Thus, the designation "B" appeared briefly in the literature \[[@CR40]\]. The mRNA was subsequently cloned as SLC6A19 by Kekuda and colleagues \[[@CR41]--[@CR43]\], and the literature now alternatively refers to the functional properties of expressed SLC6A19 as either B^0^ or B^0^AT1 (sodium-dependent cloned B^0^ Amino acid Transporter number 1).

B^0^AT1 is expressed prominently in apical membranes of renal proximal tubule and small intestine, as well as other nutrient absorptive epithelia (Table [3](#Tab15_3_149577_1_En){ref-type="table"}). Actually, B^0^AT1 is expressed all along the gastrointestinal tract intestine \[[@CR44]\], with dominance in jejunum and ileum (Fig. [9](#Fig15_9_149577_1_En){ref-type="fig"}). Fig. 9Relative mRNA expression of system B^0^ (B^0^AT1 polypeptide monomer transporter from SLC6A19 gene) in various regions of the gastrointestinal tract: esophagus (E), stomach (S), duodenum (D), jejunum (J), ileum (I), colon (C), rectum (R), as well as pancreas (P). Real-time PCR forward primer was GTGTGGACAGGTTCAATAAGGACAT; reverse primer was CCACGTGACTTGCCAGAAGAT. Data points from individual patients redrawn from figure originally erroneously labeled in Terada et al. \[[@CR44]\]. Means are shown as *horizontal bars* for each intestinal region

The B^0^AT1 functional transport system represents an apical membrane polypeptide monomer activated by a sodium-dependent Cl^−^ independent mechanism. A putative structure-function relationship has been determined by Broer and colleagues \[[@CR6], [@CR45]\] , and a putative kinetic mechanism (see Fig. [10](#Fig15_10_149577_1_En){ref-type="fig"}) has been worked out by the laboratories of Broer and Verrey \[[@CR46]--[@CR48]\]. Fig. 10Kinetic model of B^0^AT1 transporter. Apical membrane carrier (C^i^ intracellular; C^o^ extracellular) first binds substrate amino acid AA then Na^+^ activator, as influenced by membrane potential ΔΨ. Preferred pathway shown with *bold arrows*. On the basis of models from Bröer's group \[[@CR46], [@CR47]\] and Verrey's group \[[@CR48]\]

Regulation of Amino Acid Transport by ACE2 and Its Homolog Collectrin {#Sec10}
=====================================================================

Figure [7](#Fig15_7_149577_1_En){ref-type="fig"} above shows the requirement of ACE2 for apical membrane functioning of B^0^AT1. Therefore, ACE2 is also necessary for cooperative functioning of the other transporters that interact with B^0^AT1, such as the b^0,+^AT/rBAT heterodimer complex.

Many years ago our laboratory demonstrated that human intestinal apical membranes expressed angiotensin converting enzyme (ACE) \[[@CR49]--[@CR51]\], which is a peptidyl dipeptidase that removes a dipeptide from the C-terminus of peptides; we suggested that the function of this nonaminopeptidase was to hydrolyze peptides for subsequent absorption by transporters. However, ACE2, which is a carboxypeptidase, was subsequently discovered in apical membranes in kidney \[[@CR52]\] and intestine \[[@CR53]--[@CR55]\]. ACE2 fortuitously is recognized as a binding receptor by a severe acute respiratory syndrome (SARS) coronavirus \[[@CR56]\] (SARS-CoV), consistent with clinical observations that SARS-CoV causes severe gastrointestinal complications. A presumed intended biological function of ACE2 is proper trafficking and functioning of B^0^AT1, and then membrane removal of the C-terminal single neutral amino acid from nutrient peptides. These particular amino acid products of ACE2 hydrolysis are the very amino acids that are B^0^AT1 substrates \[[@CR45]\]. A homologue of ACE2 found in kidney, collectrin, was shown to be a mediator of neutral amino acid transport activity and regulator of blood pressure \[[@CR45], [@CR57]--[@CR59]\] via the transport interplay of arginine and neutral amino acids through cooperation of B^0^AT1 and the b^0,+^AT/rBAT transporters, as shown in Fig. [7](#Fig15_7_149577_1_En){ref-type="fig"}. Collectrin knock out mice demonstrated reduced expression of apical membrane B^0^AT1, rBAT, and b^0,+^AT, as well as impaired intracellular trafficking of EAAC1, with the residual activity of B^0^AT1 attributable to ACE2. Broer's laboratory demonstrated that the R240 moiety of B^0^AT1 interacts with intestinal ACE2 permitting proper apical membrane trafficking and expression of this sodium-dependent amino acid transporter \[[@CR45]\].

SLC6A19 genomic DNA is composed of 19 exons and 18 introns on human chromosome 5 at location 5p15.33. Mutations in SLC6A19 on more and more alleles of patients with Hartnup disorder gives the aminoaciduria phenotype manifested in both intestine and kidney \[[@CR3], [@CR45], [@CR60]--[@CR63]\]. Dysfunctional SLC6A19 mutants of B^0^AT1 expressed in renal proximal tubule, arising from a variable number of tandem repeat minisatellite polymorphisms, are likely to be a risk factor for hypertension \[[@CR64]\]. Figure [11](#Fig15_11_149577_1_En){ref-type="fig"} shows genomic intron/exon relationships concerning known SLC6A19 mutations, and a particular minisatellite repeat unit in intron 9 of SLC6A19 encodes a dysfunctional B^0^AT1 associated with essential hypertension in humans \[[@CR64]\]. Interestingly, SLC6A18 encoding another "orphan" transporter, XTRP2, which serves glycine reabsorption in kidney, is adjacent to the SLC6A19 gene sequence, although SLC6A18 minisatellites are not involved in hypertension \[[@CR65]\]. Fig. 11Allelic structure of human genomic DNA near the SLC6A19 gene. Monomeric transporter B^0^AT1 polypeptide is encoded by 19 exons of SLC6A19 (location 5p15.33) indicated by *vertical bars*. Minisatellite repeat (MS) positions are indicated by *triangles*, and introns are indicated by *short horizontal bars* under *triangles*. Minisatellite repeat unit MS7 in intron 9 of SLC6A19 encodes a dysfunctional B^0^AT1 associated with hypertension. The sequence of MS7 is shown. TERT (telomerase reverse transcriptase) and SLC6A18 appear adjacent upstream at 5p15.33. Adapted from Seol et al. \[[@CR64]\]

Taken together, these elegant studies suggest that epithelial cell regulation of amino acid transport activity likely involves other undiscovered modulation factors that are affective either through trafficking or perhaps other mechanisms. One overall physiological relevance might be that collectrin in renal tubule membranes or allelic mutations could affect blood pressure \[[@CR59], [@CR64]\].

Summary {#Sec11}
=======

This review summarized the current view of amino acid transport by epithelial cells of vertebrates. A wide variety of transporter proteins are expressed in apical and basolateral membranes and collectively play complex interactive roles in controlling the entire organism's overall metabolism of amino acids. Regulation of the transport systems can be manifested at many levels, including gene splicing and promoter regulation, interactions between requisite subunits of oligomers, thermodynamic electrochemical gradients contributed by ion exchangers, overlap of substrate specificity, selective tissue distribution, and specific spatial distribution of transporters leading to net vectorial flow of the amino acids. The next frontier for workers in this field is to uncover a comprehensive molecular understanding of the manner by which epithelial cells signal gene expression of transporters as triggered by substrates, hormones or other triggers, to further understand the trafficking and interactions among multimeric transport system proteins, to extend discoveries of novel small drug substrates for oral and ocular delivery, and to examine gene therapy or nanotherapy of diseases using small molecules delivered via amino acid transporters.
